Pioglitazone in Parkinson's Disease Study
Participants are currently being recurited to take part in a multi-site NIH-sponsored study investigating the possible neuroprotective properties of Pioglitazone (ACTOS (R)) in individuals with early stage Parkinson's disease (PD). The purpose of this study is to determine whether Pioglitazone, a drug currently approved by the FDA to treat type II diabetes, may be useful in interrupting the progression of PD. Potential participants must be able to attend six on-site visits over the course of approximately twelve months. Additionally, participants must currently be taking 1mg of rasagiline per day or 10mg of selegiline per day.